ESMO open
Response to Letter to the Editor Re: Impact of the Prosigna assay on neoadjuvant treatment decision making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study.
C Corti, S M Tolaney
Published: 202510.1016/j.esmoop.2025.105861
No abstract available for this study.